Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy (original) (raw)

Abstract

Purpose

Magnesium oxide (MgO), a short-term osmotic laxative, is converted into MgCl2 under acidic condition in the stomach and then Mg(HCO3)2 in the intestinal tract, where Mg(HCO3)2 induces the water exudation into the intestine. This indicates that the laxative effect of MgO could be attenuated under the suppressed gastric acid secretion. In this study, the possible interaction of MgO with gastric acid secretion inhibitors was evaluated by using electronic patient records of MgO dosage levels.

Methods

Defecation was controlled with MgO alone in some patients after colon surgery (n = 67) and after total gastric resection (n = 4). Some other patients were treated with a combination use of MgO and H2 receptor antagonist (H2RA) (n = 14) or proton pump inhibitor (PPI) (n = 27). The possible drug interaction of MgO with H2RA or PPI was evaluated by comparing dosage levels of MgO used in controlling defecation.

Results

In controlling defecation, the daily dosage levels of MgO in patients taking H2RA or PPI and patients with total gastric resection were significantly higher than those patients taking MgO alone after colon surgery. The ratios of good constipation control (controlled well at the dosing level of 1,000 mg MgO) in patients taking H2RA or PPI were significantly lower than that in patients treated with MgO alone. In an in vitro study, the solubility of MgO at pH 4.5 was quite low, as compared with that at pH 1.2.

Conclusions

When patients received H2RA or PPI, the laxative effect of MgO is decreased possibly due to the low solubility of MgO at the higher gastric pH and less generation of MgCl2 and Mg(HCO3)2. Higher dosing level of MgO or another laxative should be used in patients taking H2RA or PPI, as well as the case of patients with total gastric resection.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Nakamura T (1992) Side effects of long-term use of magnesium oxide. Nihon Iji Shimpo 3540:177–178
    Google Scholar
  2. Howden CW, Hunt RH (1987) Relationship between gastric secretion and infection. Gut 28:96–107
    Article CAS PubMed Central PubMed Google Scholar
  3. Cook GC (1985) Infective gastroenteritis and its relationship to reduced gastric acidity. Scand J Gastroenterol Suppl 111:17–23
    Article CAS PubMed Google Scholar
  4. Mahachai V, Reilly P, Thomson AB (1984) Comparative effects of pirenzepine and cimetidine, alone and in combination, on 24-hour gastric acidity in duodenal ulcer disease. Clin Ther 7:98–111
    CAS PubMed Google Scholar
  5. Hongo M, Ohara S, Hirasawa Y, Abe S, Asaki S, Toyota T (1992) Effect of lansoprazole on intragastric pH. Dig Dis Sci 37:882–890
    Article CAS PubMed Google Scholar
  6. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH (1997) The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 19:1013–1023
    Article CAS PubMed Google Scholar
  7. Huang JQ, Goldwater DR, Thomson AB, Appelman SA, Sridhar S, James CF, Chiu YL, Pilmer BL, Keith RG, Hunt RH (2002) Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment Pharmacol Ther 16:425–433
    Article CAS PubMed Google Scholar
  8. Röhss K, Wilder-Smith C, Nauclér E, Jansson L (2004) Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Invest 24:1–7
    Article Google Scholar
  9. Fimmel CJ, Etienne A, Cilluffo T, von Ritter C, Gasser T, Rey JP, Caradonna-Moscatelli P, Sabbatini F, Pace F, Bühler HW (1985) Long-term ambulatory gastric pH monitoring: Validation of a new method and effect of H2 antagonists. Gastroenterology 88:1842–1851
    CAS PubMed Google Scholar
  10. Merki HS, Witzel L, Walt RP, Neumann J, Scheurle E, Mappes A, Krammisch H, Heim J, Kaufmann D, Roehmel J (1988) Double blind comparison of the effects of cimetidine, ranitidine, famotidine and placebo on intragastric acidity in 30 normal volunteers. Gut 29:81–84
    Article CAS PubMed Central PubMed Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Chugoku Rosai Hospital, 1-5-1 Hiro-Tagaya, Kure, Hiroshima, 737-0193, Japan
    Miho Yamasaki, Sachiyo Funakoshi, Shohei Matsuda, Tomoko Imazu, Yoshiaki Takeda & Yorinobu Maeda
  2. Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hiro-koshingai, Kure, Hiroshima, 737-0112, Japan
    Teruo Murakami

Authors

  1. Miho Yamasaki
    You can also search for this author inPubMed Google Scholar
  2. Sachiyo Funakoshi
    You can also search for this author inPubMed Google Scholar
  3. Shohei Matsuda
    You can also search for this author inPubMed Google Scholar
  4. Tomoko Imazu
    You can also search for this author inPubMed Google Scholar
  5. Yoshiaki Takeda
    You can also search for this author inPubMed Google Scholar
  6. Teruo Murakami
    You can also search for this author inPubMed Google Scholar
  7. Yorinobu Maeda
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toMiho Yamasaki.

Rights and permissions

About this article

Cite this article

Yamasaki, M., Funakoshi, S., Matsuda, S. et al. Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy.Eur J Clin Pharmacol 70, 921–924 (2014). https://doi.org/10.1007/s00228-014-1694-x

Download citation

Keywords